Business Context and Reporting Period
This Form 8-K is a current report filed by Pro-Pharmaceuticals, Inc. (not Galectin Therapeutics Inc.) on January 10, 2011. The filing updates a previous report from January 6, 2011, regarding the sale of Series C Super Dividend Convertible Preferred Stock.
Key Financial Metrics
- Capital Raised: $130,000 in gross proceeds.
- Shares Issued: 13 shares of Series C Preferred Stock.
- Price Per Share: $10,000.
- Underwriting Costs: None (no discounts or commissions).
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for operating revenue, net income, operating cash flow, or margins.
- Debt/Liquidity: The filing text does not provide a clear value for total debt or liquidity ratios.
Material Changes
The company issued an additional 13 shares of Series C Preferred Stock subsequent to the January 6, 2011 filing. This transaction increased the total aggregate shares sold in this series to 225 shares (212 previously reported + 13 new shares).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure that the securities were sold in reliance on exemptions from registration under Section 4(2) of the Securities Act and Rule 506 of Regulation D. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the total number of Series C Preferred Stock shares outstanding after this issuance.
- Review the "Certificate of Designation" (Exhibit 3.1) for dividend rates, conversion terms, and liquidation preferences.
- Confirm the use of the $130,000 gross proceeds in subsequent financial statements.
- Check for any additional unregistered sales of equity securities not covered in this specific update.